European regulators spurn Agios' AML drug Tibsovo, unconvinced by the same thin PhI data that won over the FDA
European regulators aren’t as impressed with Agios’ single-arm data from the Phase I study for Tibsovo as the FDA proved to be 2 years ago …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
